Biogen ahead of Q1 earnings đź“ŠPatient Capital sees opportunity in Alzhaimer drug

8:27 pm 23 April 2024

US biopharmaceutical company, Biogen (BIIB.US), will report its results tomorrow; before Wall Street opens. Value-oriented fund Patient Capital Management on "Opportunity Equity Strategy" shared its observations with investors. In Q1, the commenting company said, the fund provided its investors with an 11.8% return net of fees, compared to a 10.6% gain from the S&P 500 index. The firm indicated that one of its biggest investment choices in Q1 was the stock of US pharmaceutical company Biogen (BIIB.US). Biogen discovers, develops, manufactures and delivers therapies for the treatment of neurological and neurodegenerative diseases. The company's shares have been underselling pressure for many months and have lost more than 30% since April 2023. The stock is trading flat today.

Alzhaimer's drug - an opportunity for Biogen?

  • Biogen focuses on treating multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. The company has been under pressure since the FDA's approval of Aduhelm, a drug to inhibit Alzheimer's (June 2021).
  • The approval process has been criticized due to the limited effectiveness of the drug's therapy. Patient Capital believes that the company now has a new, highly regarded CEO, Christopher Viehbacher, a rationalized cost structure and more disciplined investment management;
  • Patient Capital assessed that the company already has another Alzheimer's drug, Leqembi, which is more effective than Aduhelm and fully approved. The fund assessed that while progress in the use of Leqembi has been slow so far, it still creates great long-term potential for a higher patient population. Analysts pointed out that this potential may be 'dramatically underestimated' at present.
  • As a result, the fund maintained that Biogen now offers an opportunity to buy forward-looking, high-performing healthcare assets with a strong track record of delivering great products. The fund summarized Legembi's outlook and stressed that "it's not often that you see such a risk/reward ratio in the market, and we opportunistically took advantage of that."
  • Analysts at Oppenheimer 2 days ago lowered their target price, for Biogen shares from $290 to $270 which would still imply approx. 40% upside potential from current valuation levels. Wedbush, on the other hand, lowered its recommendation significantly, from $245 to $213 per share. 
  • The value (Equity) generated by Biogen as of 2021 has increased by $4 billion, to $14 billion, against an unchanged long-term debt level of about $6 billion. In February, the company said it expected $15 to $16 in earnings per share for the full year 2024 (about 5% y/y growth). A possible upward revision of these forecasts could help the company's stock. Wall Street still seems skeptical looking ahead to tomorrow's report; looking at recent analyst revisions.

...But the world is still skeptical

  • Today's Reuters report suggests that Biogen's partner Japanese Eisai (as well as the company itself) launch faces a fundamental problem, because physicians still see Alzheimer's disease as untreatable. Alzheimer's drug adoption in US slowed by doctors' skepticism 9 months after the drug debut.
  • Eisai has recently outlined a range of ways to kick-start Leqembi’s lackluster launch, from increasing the number of neurology account specialists to adding a subcutaneous option. Spherix report found few of the 75 surveyed U.S. neurologists “Consider Leqembi to be a significant medical advance over other historical AD treatments.” Less than half of the neurologists were actively recommending the drug to patients.

Biogen shares (BIIB.US)

Biogen shares have been outperforming companies like Eli Lilly (LLY.US) for years. The current, D1-based RSI indicates levels near oversold levels, near 30 points. Levels of $190 appear key to hold in the medium term, as they reflect the 'local lows' of 2013 and 2022. On February 13, the company reported results that disappointed Wall Street expectations.

Start investing today or test a free demo

Open real account TRY DEMO Download mobile app Download mobile app

Source: xStation5

Source: Bloomberg Financial LP, XTB Research

Source: Bloomberg Finance LP, XTB Research

The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.

Share:
Back
Xtb logo

Join over 1 000 000 XTB Group Clients from around the world.

We use cookies

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

This group contains cookies that are necessary for our websites to work. They take part in functionalities like language preferences, traffic distribution or keeping user session. They cannot be disabled.

Cookie name
Description
SERVERID
userBranchSymbol cc 2 March 2024
adobe_unique_id cc 1 March 2025
__hssc cc 8 September 2022
SESSID cc 2 March 2024
__cf_bm cc 8 September 2022
intercom-id-iojaybix cc 26 November 2024
intercom-session-iojaybix cc 8 March 2024

We use tools that let us analyze the usage of our page. Such data lets us improve the user experience of our web service.

Cookie name
Description
__hstc cc 7 March 2023
__hssrc

This group of cookies is used to show you ads of topics that you are interested in. It also lets us monitor our marketing activities, it helps to measure the performance of our ads.

Cookie name
Description
hubspotutk cc 7 March 2023

Cookies from this group store your preferences you gave while using the site, so that they will already be here when you visit the page after some time.

Cookie name
Description

This page uses cookies. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. For more information see our Privacy Policy You can manage cookies by clicking "Settings". If you agree to our use of cookies, click "Accept all".

Change region and language
Country of residence
Language